Valbiotis SAS - Asset Resilience Ratio

Latest as of December 2025: 45.67%

Valbiotis SAS (ALVAL) has an Asset Resilience Ratio of 45.67% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ALVAL working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€6.57 Million
≈ $7.68 Million USD Cash + Short-term Investments

Total Assets

€14.39 Million
≈ $16.82 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2025)

This chart shows how Valbiotis SAS's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ALVAL total asset value.

Liquid Assets Composition Over Time

This chart breaks down Valbiotis SAS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Valbiotis SAS to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €6.57 Million 45.67%
Short-term Investments €0.00 0%
Total Liquid Assets €6.57 Million 45.67%

Asset Resilience Insights

  • Very High Liquidity: Valbiotis SAS maintains exceptional liquid asset reserves at 45.67% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Valbiotis SAS Industry Peers by Asset Resilience Ratio

Compare Valbiotis SAS's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Nestle S.A.
SW:NESN
Packaged Foods 2.01%
Uni-President Enterprises Corp
TW:1216
Packaged Foods 4.53%
The Magnum Ice Cream Company N.V.
AS:MICC
Packaged Foods 0.11%
Conagra Brands, Inc.
NYSE:CAG
Packaged Foods 0.29%
Alfa S.A.B. de C.V.
MX:ALFAA
Packaged Foods 0.74%
Premium Brands Holdings Corporation
TO:PBH
Packaged Foods 0.49%
Chongqing Fuling Zhacai Group Co Ltd
SHE:002507
Packaged Foods 27.78%
Juewei Food Co Ltd
SHG:603517
Packaged Foods 3.18%

Annual Asset Resilience Ratio for Valbiotis SAS (2015–2025)

The table below shows the annual Asset Resilience Ratio data for Valbiotis SAS.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 45.67% €6.57 Million
≈ $7.68 Million
€14.39 Million
≈ $16.82 Million
+5.34pp
2024-12-31 40.33% €7.91 Million
≈ $9.24 Million
€19.61 Million
≈ $22.92 Million
+32.62pp
2023-12-31 7.70% €2.57 Million
≈ $3.00 Million
€33.31 Million
≈ $38.94 Million
+5.71pp
2022-12-31 1.99% €541.00K
≈ $632.49K
€27.17 Million
≈ $31.77 Million
+0.09pp
2021-12-31 1.90% €541.00K
≈ $632.49K
€28.48 Million
≈ $33.29 Million
-1.24pp
2020-12-31 3.14% €660.00K
≈ $771.61K
€21.00 Million
≈ $24.55 Million
-8.98pp
2019-12-31 12.12% €1.82 Million
≈ $2.13 Million
€15.02 Million
≈ $17.55 Million
-73.47pp
2018-12-31 85.59% €10.19 Million
≈ $11.91 Million
€11.91 Million
≈ $13.92 Million
+2.21pp
2017-12-31 83.38% €10.60 Million
≈ $12.39 Million
€12.71 Million
≈ $14.86 Million
+50.80pp
2016-12-31 32.57% €529.00K
≈ $618.46K
€1.62 Million
≈ $1.90 Million
+1.94pp
2015-12-31 30.63% €355.01K
≈ $415.05K
€1.16 Million
≈ $1.35 Million
--
pp = percentage points

About Valbiotis SAS

PA:ALVAL France Packaged Foods
Market Cap
$30.21 Million
€25.84 Million EUR
Market Cap Rank
#24138 Global
#385 in France
Share Price
€0.73
Change (1 day)
-2.93%
52-Week Range
€0.55 - €1.21
All Time High
€10.54
About

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; T… Read more